Navigation Links
Patients With Asthma and Seasonal Allergies Respond Better to Advair(R) for Their Asthma Than Singulair(TM)
Date:5/18/2008

Study Suggests that Adding Singulair to Advair Offers no Additional

Improvement in Overall Asthma Control

RESEARCH TRIANGLE PARK, N.C. and TORONTO, May 18 /PRNewswire-FirstCall/ -- Patients with both asthma and allergic rhinitis, or seasonal allergies, experience significantly better lung function when treated with Advair Diskus(R) (fluticasone propionate and salmeterol inhalation powder) as compared with Singulair (montelukast sodium). The results of the 660-subject study were presented today at the International Conference of the American Thoracic Society meeting in Toronto.

The study also showed patients treated with Advair plus Singulair saw no measurable improvement compared to patients treated with Advair alone in their asthma symptoms or albuterol use. In another comparison patients using Advair plus the intranasal corticosteroid, fluticasone propionate nasal spray, saw significant improvement in daytime nasal symptoms compared to patients treated with Advair plus Singulair (p<0.001).

"These findings give us a greater understanding of how to treat patients with asthma and seasonal allergies, two diseases that often are seen in tandem," said Rohit Katial, MD, National Jewish Medical Research Center. "By using the right combination of treatments, physicians can help patients gain relief from the symptoms of both diseases."

The study included people age 15 and up who had both persistent asthma and seasonal allergies. Patients received one of four different treatments: Advair Diskus 100/50 twice daily, Singulair 10 mg once daily, Advair 100/50 twice daily with Singulair 10 mg once daily or Advair 100/50 twice daily with fluticasone propionate nasal spray 200 mcg once daily. Those who received Advair alone had significant improvements in their morning peak expiratory flow, a measure of asthma control, as compared with Singulair alone (p<0.001). Secondary endpoints, including symptom-free days and rescue-treat
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
2. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
3. Pharmacopeias First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
4. New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
5. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
6. Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer
7. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
8. New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R)
9. AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients
10. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
11. Prism Glasses Expand the View for Patients with Hemianopia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... CHAGRIN FALLS, Ohio , July 30, 2015 /PRNewswire/ ... in his OMTEC® 2015 keynote address last month that ... business models in order to gain the efficiencies—and develop ... future. Dr. Barsoum,s comments were preceded by ... Tornier, avid entrepreneur and OMTEC moderator, who stressed that ...
(Date:7/30/2015)... , July 30, 2015 ... research report with market overview, trends, DRO ... porter analysis, recent developments, competitive scenario and ... Industry Insight: Biosensors Market Development and Demand ... http://photos.prnewswire.com/prnh/20150727/756778 ) Explore more ...
(Date:7/30/2015)... 2015 Vermillion, Inc. (VRML), a ... announced today it will report its second ... close on Thursday, August 13, 2015, followed ... at 4:30pm Eastern.Conference Call and Webcast:  ... Pacific  Domestic: , 888-430-8691International: ...
Breaking Medicine Technology:Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5
... Analysis of SPIRIT II and SPIRIT III Data Confirms Patients ... Death, a Heart Attack or a ... TAXUS(R) at Two Years, WASHINGTON, Oct. 13 Data ... randomized clinical,trials demonstrated that the XIENCE V(TM) Everolimus Eluting Coronary ...
... Class, of Stent with Polyzene(R)-F Surface ... for Long-Term,Dual Antiplatelet Therapy, WASHINGTON, ... today,s,"Innovative Devices and Futuristic Therapies" session ... (TCT) scientific,symposium, sponsored by the Cardiovascular ...
Cached Medicine Technology:Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 2Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 3Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 4Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 512-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 212-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 312-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 4
(Date:7/31/2015)... ... July 31, 2015 , ... The alarm was ringing. Hugh Chatfield, survivor of a severe 1987 ... he recalled that his equipment was set up to depict the newly poured concrete. With ... bed. , The photo speaks for itself. Chatfield is also a highly praised safety and ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... blog post that encourages the understanding and treatment of ankle sprains. A common ... in-home remedies. This can be dangerous if the condition augments and causes more ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Ticket Down ... in Birmingham. The U.S. Women's National Soccer Team will face the Australia Women's ... on Thursday, September 17th at Ford Field in Detroit and the second match will ...
(Date:7/31/2015)... ... 31, 2015 , ... everMaya ( http://evermaya.com/ ), a Fashion ... will be named for Madeline Stuart, an 18-year-old model from Brisbane, Australia. Ms. ... with Down syndrome, gracing the front pages of publications across the world. everMaya ...
(Date:7/31/2015)... Detroit, MI (PRWEB) , ... July 31, 2015 , ... Ticket Down is a reputable ... The U.S. Women's National Soccer Team will face the Australia Women's National Team in conjunction ... by a score of 5-2. Carli Lloyd from the USA team was awarded the ...
Breaking Medicine News(10 mins):Health News:Absolute PhysioCare & Sports Rehab Promotes Understanding & Treatment of Ankle Sprains 2Health News:Cheap USA vs. Australia Tickets at Legion Field in Birmingham, AL: Ticket Down Slashes Ticket Prices for Australia vs. USWNT at Legion Field 2Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:Cheap USA vs. Australia Tickets at Ford Field in Detroit, MI: Ticket Down Slashes Ticket Prices for Australia vs. USWNT International Friendly Match at Ford Field 2
... 26 Researchers at Wayne State University ... that may one day lead to new treatments.Prostate cancer, ... affects one in six men. In 2008, nearly ... nearly 186,000 were newly diagnosed, and approximately 28,000 died ...
... interactive pediatric healthcare education and resources for hospitals, physicians, and ... ... Wilmington, DE (PRWEB) March 26, 2009 -- Emmi Solutions ... and information programs, and KidsHealth ®, the largest provider ...
... Venture Capital Community to Drive Innovation through Investment Opportunities ... 26 The 510(k) program is under siege from ... complained in a letter to Congress that CDRH management ... 510(k)s. They followed that complaint to Congress with ...
... 26, 2009 Nearly 90 percent of the 700,000 strokes ... a blockage of blood vessels supplying the brain, known ... Catheterization and Cardiovascular Interventions , the official journal of ... solid evidence of the effectiveness of catheter-based therapy (CBT) ...
... a Mayo Clinic study show that a simple, noninvasive finger ... such as a heart attack or stroke, for people who ... study will be presented Tuesday, March 31, 2009 at 11:30 ... Annual Scientific Session in Orlando (0917-7).The noninvasive finger test device, ...
... Sure There,s a Rollover Bar Above Your Head , ... Bloomington, MN ... buyers of previously owned commercial zero-radius-turn (ZRT) mowers to check that each ... to a roll bar on a race car, an overhead ROPS and ...
Cached Medicine News:Health News:Wayne State University Scientists ID New Biomarker for Prostate Cancer 2Health News:Emmi + KidsHealth = Prescription for Informed and Involved Patients 2Health News:Emmi + KidsHealth = Prescription for Informed and Involved Patients 3Health News:FDA Fireside Chat @ The 8th Annual MedTech Investing Conference May 6-7, 2009 2Health News:FDA Fireside Chat @ The 8th Annual MedTech Investing Conference May 6-7, 2009 3Health News:FDA Fireside Chat @ The 8th Annual MedTech Investing Conference May 6-7, 2009 4Health News:Individualized stroke treatment available for patients, though underutilized 2Health News:Mayo Study Shows Simple Finger Device May Help Predict Future Heart Events, Such as Heart Attack 2Health News:Mayo Study Shows Simple Finger Device May Help Predict Future Heart Events, Such as Heart Attack 3Health News:Safety Alert for Buyers of Used Commercial Zero Turn Mowers 2Health News:Safety Alert for Buyers of Used Commercial Zero Turn Mowers 3Health News:Safety Alert for Buyers of Used Commercial Zero Turn Mowers 4Health News:Safety Alert for Buyers of Used Commercial Zero Turn Mowers 5
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: